

Dylan Kahl

PATENT AGENT

Patents and
Innovations

dkahl@wsgr.com
415-947-2479



FOCUS AREAS

Intellectual Property
Life Sciences
Patents and Innovations

EXPERIENCE

Dr. Dylan Kahl is a patent agent at Wilson Sonsini Goodrich & Rosati. He is a member of the firm's patents and innovations practice, where he assists with various matters related to the diligence for and the preparation and prosecution of patent applications in the fields of chemistry, medicinal chemistry, pharmaceuticals, biochemistry, and biotechnology.

During graduate school, Dylan studied under Dr. Scott D. Larsen at the Valtech Medicinal Chemistry Core, where he worked on a variety of projects related to small-molecule drug discovery and design, including the design and synthesis of potent small-molecule anti-fibrotic agents as lead compounds and the production of many successful affinity pull-down probes for target identification studies. Given his background, Dylan has a strong understanding of technological innovations spanning both the fields of chemistry and biology.

CREDENTIALS

Education

- Ph.D., Medicinal Chemistry, University of Michigan, 2018
- B.S., Biochemistry, Arizona State University, 2014
Cum Laude; Dean's List, 2012-2014; Recipient, New American University Scholar—Dean's Award, 2010-2014

Admissions

- U.S. Patent and Trademark Office

INSIGHTS

Select Publications

- Co-author, "5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma," 62(9) *Journal of Medicinal Chemistry* 4350-69, May 9, 2019
- Co-author with E.M. Lisabeth et al., "Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds," 2(2) *ACS Pharmacology & Translational Science* 92-100, 2019